-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Initiates Coverage On Eton Pharmaceuticals with Buy Rating, Announces Price Target of $60

Benzinga·07/17/2026 10:24:46
Listen to the news
Canaccord Genuity analyst Gary Nachman initiates coverage on Eton Pharmaceuticals (NASDAQ:ETON) with a Buy rating and announces Price Target of $60.